Oral Oresentation 4

3:48 PM - 3:54 PM JST(6:48 AM - 6:54 AM UTC)

[O04-04] Efficacy and safety of mirikizumab as induction therapy for Chinese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the phase 3 Lucent-1 study

*Zhihua Ran^1,2, Jun Shen¹, Yan Chen³, Juan Luo⁴, Yufang Wang⁵, Xueli Ding⁶, Hao Fang⁷, Dan Tang⁸, Chenxi Qian⁸, Jiao Yu⁸ (1. Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2. Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China, 3. The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, 4. The First Affiliated Hospital of Kunming Medical University, Kunming, China, 5. West China Hospital of Sichuan University, Chengdu, China, 6. The Affiliated Hospital of Qingdao University, Qingdao, China, 7. Taian City Central Hospital, Taian, China, 8. Eli Lilly and Company, Shanghai, China)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.